Text and Data Mining valid from 2019-03-29
Received: 4 September 2018
Accepted: 16 January 2019
First Online: 29 March 2019
Ethics approval and consent to participate
: Approval for the study was obtained from the Dana-Farber/Harvard Cancer Center Institutional Review Committee.
: Not Applicable.
: GSN: Former employee of Biocon and current employee of Leap Therapeutics Inc.SSW: None to declare.AEW: None to declare.EIB: Research funding paid to the institution – BMS (Bristol-Myers Squibb) and Merck. Consulting for BMSRH: Grant support from BMS, Novartis.Consultant: Tango Therapeutics FSH reports other from Bristol-Myers Squibb to institution, grants, personal fees and other from Bristol-Myers Squibb, personal fees from Merck, personal fees from EMD Serono, personal fees from Novartis, personal fees from Takeda, personal fees from Surface, personal fees from Genentech/Roche, personal fees from Incyte, personal fees from Apricity, personal fees from Bayer, personal fees from Aduro, personal fees from Partners Therapeutics, personal fees from Sanofi, personal fees from Pfizer, personal fees from Pionyr, personal fees from Verastem, other from Torque, personal fees from Compass Therapeutics, outside the submitted work; In addition, Dr. Hodi has a patent Methods for Treating MICA-Related Disorders (#20100111973) with royalties paid, a patent Tumor antigens and uses thereof (#7250291) issued, a patent Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (#20170248603) pending, a patent Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms (#20160340407) pending, a patent Therapeutic peptides (#20160046716) pending, a patent Therapeutic Peptides (#20140004112) pending, a patent Therapeutic Peptides (#20170022275) pending, a patent Therapeutic Peptides (#20170008962) pending, a patent THERAPEUTIC PEPTIDESÐherapeutic PeptidesÐatent number: 9402905 issued, and a patent METHODS OF USING PEMBROLIZUMAB AND TREBANANIB pending.JDS: Research funding paid to the institution – BMS, Merck; Scientific Advisory Board - BMS, AstraZeneca, Debiopharm, Nanobiotix; Consulting - Tilos.PAO: Research funding paid to the institution - BMS, Merck, AstraZeneca, Celldex, CytomX, Neon Therapeutics, ARMO Biosciences, Pfizer;Consulting: BMS, Merck, Genentech, Pfizer, Novartis, CytomX, Celldex, Neon Therapeutics, Array, Amgen.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.